These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 201375)

  • 1. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
    Kleinman R; Dray S
    Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The allogeneic effect on tumor growth. I. Inhibition of a murine plasmacytoma, MOPC 315, by the graft-vs-host reaction.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1441-8. PubMed ID: 15034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune RNA-mediated transfer of tumor antigen responsiveness to unresponsive peritoneal exudate cells from tumor-bearing animals.
    Braun DP; Dray S
    Cancer Res; 1977 Nov; 37(11):4138-44. PubMed ID: 908048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The allogeneic effect on tumor growth. II. Suppression of both ascitic and solid MOPC 315 plasmacytoma by the graft-vs-host reaction, with pathologic correlation.
    Osborne DP; Katz DH
    J Immunol; 1977 Apr; 118(4):1449-55. PubMed ID: 15035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):145-52. PubMed ID: 6972902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB; Dray S
    Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of plasmacytomas on serum immunoglobulin levels of BALB/c mice.
    Fenton MR; Havas HF
    J Immunol; 1975 Feb; 114(2 pt 2):793-801. PubMed ID: 1089719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved.
    Cihak J; Ziegler HW; Kölsch E
    Immunology; 1981 May; 43(1):133-43. PubMed ID: 6265346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of subcutaneously administered 2,6,10,14-tetramethylpentadecane on plasmacytoma growth.
    Platica M; Bojko C; Steiner G; Hollander VP
    Cancer Res; 1980 Jul; 40(7):2229-33. PubMed ID: 6248200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of anti-MOPC-315 cytotoxicity in uneducated or in vitro educated spleen cells from normal or MOPC-315 tumor-bearing mice pretreated in vivo with Bacillus Calmette-Guérin.
    Braun DP; Mokyr MB; Dray S
    Cancer Res; 1978 Jun; 38(6):1626-32. PubMed ID: 647676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
    Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
    J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
    Takesue BY; Pyle JM; Mokyr MB
    Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
    Gorelik L; Rubin M; Prokhorova A; Mokyr MB
    J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.